

31 March 2022

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of April 2022 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.Pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/Pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date
Buprenorphine with naloxone	Tab sublingual 2 mg with 0.5 mg naloxone; 28 tablet blister pack	\$18.37	\$11.76	Buprenorphine Naloxone BNM (Boucher and Muir)	1 July 2022	1 December 2022
Buprenorphine with naloxone	Tab sublingual 8 mg with 2 mg naloxone; 28 tablet blister pack	\$53.12	\$34.00	Buprenorphine Naloxone BNM (Boucher and Muir)	1 July 2022	1 December 2022

2. *Tenders awarded to Pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Citalopram hydrobromide ¹	Tab 20 mg; 84 tablet blister pack	\$1.91	\$2.86	Celapram (Viatris)	1 October 2022	1 March 2023	PSM Citalopram (PSM) ²
Clonidine hydrochloride ³	Tab 25 mcg; 112 tablet blister pack	\$36.50	\$29.32	Clonidine Teva (Teva)	1 June 2022	1 November 2022	Clonidine BNM (Boucher and Muir)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml ampoule; 10 ampoule pack	\$9.25	\$7.86	HamelN (Max Health)	1 September 2022	1 February 2023	Dexamethasone Phosphate Panpharma (Multichem)
Dexamethasone phosphate	Inj 4 mg per ml, 2 ml ampoule; 10 ampoule pack	\$16.37	\$13.10	HamelN (Max Health)	1 September 2022	1 February 2023	Dexamethasone Phosphate Panpharma (Multichem)
Emtricitabine with tenofovir disoproxil	Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate); 30 tablet bottle	\$61.15	\$15.45	Tenofovir Disoproxil Emtricitabine Mylan (Viatris)	1 July 2022	1 December 2022	Teva (Teva)
Methadone hydrochloride	Tab 5 mg; 10 tablet blister pack	\$1.40	\$1.45	Methadone BNM (Boucher and Muir)	1 September 2022	1 February 2023	Methatabs (PSM)
Tenofovir disoproxil	Tab 245 mg (300 mg as a maleate); 30 tabletbottle	\$38.10	\$15.00	Tenofovir Disoproxil Mylan (Viatris)	1 July 2022	1 December 2022	Tenofovir Disoproxil Teva (Teva)
<p>¹ Brand switch fee of \$4.50 is payable for this product from 1 March 2023 to 31 May 2023.</p> <p>² PSM Citalopram's Principal Supply Status will end on the date Celapram is listed.</p> <p>³ This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2021/22 Invitation To Tender.</p>							

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date
Buprenorphine with naloxone	Tab sublingual 2 mg with 0.5 mg naloxone; 28 tablet blister pack	\$18.37	\$11.76	Buprenorphine Naloxone BNM (Boucher and Muir)	5%	1 July 2022	1 December 2022
Buprenorphine with naloxone	Tab sublingual 8 mg with 2 mg naloxone; 28 tablet blister pack	\$53.12	\$34.00	Buprenorphine Naloxone BNM (Boucher and Muir)	5%	1 July 2022	1 December 2022

4. Tenders awarded to Pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Citalopram hydrobromide	Tab 20 mg; 84 tablet blister pack	\$1.91	\$2.86	Celapram (Viatris)	5%	1 October 2022	1 March 2023	PSM Citalopram (PSM) ⁴
Clonidine hydrochloride ⁵	Tab 25 mcg; 112 tablet blister pack	\$36.50	\$29.32	Clonidine Teva (Teva)	5%	1 June 2022	1 November 2022	Clonidine BNM (Boucher and Muir)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml ampoule; 10 ampoule pack	\$9.25	\$7.86	Hameln (Max Health)	5%	1 September 2022	1 February 2023	Dexamethasone Phosphate Panpharma (Multichem)
Dexamethasone phosphate	Inj 4 mg per ml, 2 ml ampoule; 10 ampoule pack	\$16.37	\$13.10	Hameln (Max Health)	5%	1 September 2022	1 February 2023	Dexamethasone Phosphate Panpharma (Multichem)
Droperidol	Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack	\$30.95	\$43.85	Droperidol Panpharma (Multichem)	5%	1 Novemeber 2022	1 April 2023	Droleptan (AFT)
Emtricitabine with tenofovir disoproxil	Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate); 30 tablet bottle	\$61.15	\$15.45	Tenofovir Disoproxil Emtricitabine Mylan (Viatris)	5%	1 July 2022	1 December 2022	Teva (Teva)
Methadone hydrochloride	Tab 5 mg; 10 tablet blister pack	\$1.40	\$1.45	Methadone BNM (Boucher and Muir)	5%	1 September 2022	1 February 2023	Methatabs (PSM)
Tenofovir disoproxil	Tab 245 mg (300 mg as a maleate); 30 tablet bottle	\$38.10	\$15.00	Tenofovir Disoproxil Mylan (Viatris)	5%	1 July 2022	1 December 2022	Tenofovir Disoproxil Teva (Teva)
<p>⁴ PSM Citalopram's Principal Supply Status will end on the date Celapram is listed.</p> <p>⁵This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2021/22 Invitation To Tender.</p>								

For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.